161607-38-1

Basic information

• Product Name: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol
• Synonyms: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol
• CAS NO: 161607-38-1
• Molecular Weight: 329.514
• Mol File: 161607-38-1.mol

Chemical Properties

• CAS DataBase Reference: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol(CAS DataBase Reference)
• NIST Chemistry Reference: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol(161607-38-1)
• EPA Substance Registry System: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol(161607-38-1)

Safety Data

• Hazardous Substances Data: 161607-38-1(Hazardous Substances Data)

Upstream product

• 60573-68-4 3-pyridyllithium 
• 160744-60-5 4-((tert-butyldimethylsilyloxy)methyl)benzaldehyde 
• 17624-36-1 2-pyridyllithium 
• 626-55-1 3-Bromopyridine 
• 118992-89-5 [4-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl]methanol 
• 589-29-7 p-xylylene glycol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 200400-35-7 Methyl (E)-7-[4-[4-[[(4-Cyclohexylbutyl)-amino)carbonyl)-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoate 
• 213621-08-0 (Z)-7-{4-[(S)-4-(4-Cyclohexyl-butylcarbamoyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 200400-34-6 (E)-7-{4-[(S)-4-(4-Cyclohexyl-butylcarbamoyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 213621-03-5 (Z)-7-{4-[(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethylcarbamoyl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 200400-32-4 (E)-7-{4-[(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethylcarbamoyl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 200399-71-9 (Z)-7-<4-<4-<<(4-cyclohexylbutyl)amino>carbonyl>-2-oxazolyl>phenyl>-7-(3-pyridyl)hept-6-enoic acid 
• 200399-71-9 (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(pyridin-3-yl)hept-6-enoic acid 
• 213620-93-0 (Z)-7-[4-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 200400-29-9 Methyl (E)-7-[4-[(tert-Butyldimethylsiloxy)-methyl]phenyl]-7-(3-pyridyl)hept-6-enoate 
• 213620-98-5 4-((Z)-6-Methoxycarbonyl-1-pyridin-3-yl-hex-1-enyl)-benzoic acid 
• 200400-30-2 methyl (E)-7-(4-Carboxyphenyl)-7-(pyridin-3-yl)hept-6-enoate 

Relevant articles and documents

Preparation of substituted alkenoic acids

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Carbamoyl substituted heterocycles

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

PREPARATION OF SUBSTITUTED ALKENOIC ACIDS

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives

Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid).

Carbamoyl substituted oxazoles as thromboxane receptor antagonists

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.